A detailed history of D. E. Shaw & Co., Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 33,876 shares of BCRX stock, worth $221,887. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,876
Previous 30,631 10.59%
Holding current value
$221,887
Previous $183,000 6.01%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $15,868 - $24,824
3,245 Added 10.59%
33,876 $172,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $152,542 - $207,371
30,631 New
30,631 $183,000
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $858,307 - $1.09 Million
-123,320 Reduced 92.22%
10,403 $73,000
Q1 2023

May 15, 2023

SELL
$7.94 - $11.84 $3.17 Million - $4.73 Million
-399,530 Reduced 74.92%
133,723 $1.12 Million
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $395,997 - $535,538
37,714 Added 7.61%
533,253 $6.12 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $5.35 Million - $7.34 Million
495,539 New
495,539 $6.24 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $4.1 Million - $9.28 Million
-519,050 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $7.09 Million - $12.1 Million
-613,215 Reduced 54.16%
519,050 $8.44 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $1.79 Million - $2.47 Million
159,731 Added 16.42%
1,132,265 $15.7 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $1.42 Million - $1.77 Million
100,008 Added 11.46%
972,534 $14 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $7.71 Million - $14 Million
811,723 Added 1335.0%
872,526 $13.8 Million
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $126,491 - $233,588
17,163 Added 39.33%
60,803 $618,000
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $147,066 - $375,740
43,640 New
43,640 $325,000
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $69,768 - $205,999
-36,720 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $2.76 Million - $7.08 Million
-1,722,120 Reduced 97.91%
36,720 $73,000
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $161,322 - $350,040
101,461 Added 6.12%
1,758,840 $6.07 Million
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $415,062 - $619,273
166,025 Added 11.13%
1,657,379 $4.75 Million
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $444,237 - $1.4 Million
152,659 Added 11.4%
1,491,354 $5.65 Million
Q1 2019

May 15, 2019

SELL
$7.38 - $9.72 $1.19 Million - $1.56 Million
-160,787 Reduced 10.72%
1,338,695 $10.9 Million
Q4 2018

Feb 14, 2019

SELL
$6.51 - $9.6 $1.36 Million - $2 Million
-208,837 Reduced 12.22%
1,499,482 $12.1 Million
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $410,947 - $594,831
74,447 Added 4.56%
1,708,319 $13 Million
Q2 2018

Aug 14, 2018

BUY
$4.6 - $6.52 $3.08 Million - $4.37 Million
669,566 Added 69.44%
1,633,872 $9.36 Million
Q1 2018

May 15, 2018

BUY
$4.35 - $5.82 $108,023 - $144,528
24,833 Added 2.64%
964,306 $4.6 Million
Q4 2017

Feb 14, 2018

SELL
$4.16 - $5.33 $2.3 Million - $2.95 Million
-552,844 Reduced 37.05%
939,473 $4.61 Million
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $6.12 Million - $8.91 Million
1,492,317
1,492,317 $7.82 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.22B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.